Loading
The receptor that steroid hormones switch on inside cells. In lymphoid cancers, dexamethasone and prednisone acting through it kill malignant lymphocytes directly, which is why steroids sit inside leukaemia, lymphoma and myeloma regimens as well as easing nausea and swelling. This dossier gathers the 2 products (2 approved), 178 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Ligand-activated nuclear receptor; in lymphoid cells its transcriptional programme induces apoptosis, the basis of steroid use in leukaemia, lymphoma and myeloma.
| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Acute lymphoblastic leukaemia | nearly all% | Glucocorticoid receptor expressed in lymphoblasts; prednisone response is a prognostic marker | cancer.gov |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
| Modality | Approved |
|---|---|
| Glucocorticoid 2 |
| Trial | Setting | Result | Products | ||
|---|---|---|---|---|---|
| 3 | Active | A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | - | ||
| 3 | Active | A Phase III, Multicenter, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Pomalidomide and Dexamethasone (B-Pd) Versus Pomalidomide Plus Bortezomib and Dexamethasone (PVd) in Participants With Relapsed/Refractory Multiple Myeloma (DREAMM 8) | - | ||
| 3 | Active | DREAMM 7: A Multicenter, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared With the Combination of Daratumumab, Bortezomib and Dexamethasone (D-Vd) in Participants With Relapsed/Refractory Multiple Myeloma | - | ||
| 3 | Active | DREAMM 7: A Multicenter, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared With the Combination of Daratumumab, Bortezomib and Dexamethasone (D-Vd) in Participants With Relapsed/Refractory Multiple Myeloma | - | ||
KEYNOTE-921 NCT03834506 | 3 | Negative | Metastatic castration-resistant prostate cancer progressing after androgen deprivation and one androgen receptor pathway inhibitor: pembrolizumab or placebo with docetaxel and concomitant prednisone, with dual primary endpoints of radiographic progression-free survival by blinded independent central review and overall survival | Median radiographic progression-free survival 8.6 against 8.3 months (hazard ratio 0.85, 95 percent confidence interval 0.71 to 1.01) and overall survival 19.6 against 19.0 months (0.92, 0.78 to 1.09); neither endpoint met. | |
| 3 | Active | A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination With Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects With Metastatic Castration-Resistant Prostate Cancer | - | ||
| 3 | Completed | A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations | - | ||
TRIANGLE NCT02858258 | 3 | Positive | Previously untreated mantle cell lymphoma in patients up to 65 fit for transplant: alternating R-CHOP and R-DHAP induction followed by autologous transplant (arm A), the same with ibrutinib added to induction and as two-year maintenance (arm A+I), or ibrutinib-containing induction and maintenance without transplant (arm I) | Three-year failure-free survival 88 percent with ibrutinib added to induction, transplant and maintenance against 72 percent with standard induction and transplant (hazard ratio 0.52); transplant was not shown to be superior to an ibrutinib-containing regimen without transplant (72 against 86 percent). | |
| 3 | - | A Randomized, Controlled, Open-Label Phase 3 Study of Melflufen in Combination With Daratumumab Compared With Daratumumab in Patients With Relapsed or Relapsed-Refractory Multiple Myeloma | - | ||
| 3 | - | A Randomized, Controlled, Open-label, Phase 3 Study of Melflufen/Dexamethasone Compared With Pomalidomide/Dexamethasone for Patients With Relapsed Refractory Multiple Myeloma Who Are Refractory to Lenalidomide | - | ||
| 3 | Completed | A Phase 3b Multicenter, Open-label Abiraterone Acetate Long-term Safety Study | - | ||
AALL1231 NCT02112916 | 3 | Mixed | Newly diagnosed T-cell acute lymphoblastic leukaemia and stage II to IV T-lymphoblastic lymphoma in children and young adults: a modified augmented BFM regimen with or without bortezomib during induction and delayed intensification, with prophylactic cranial radiotherapy removed for most patients | Bortezomib did not significantly improve four-year event-free survival for the whole group (83.8 against 80.1 percent) but did for T-lymphoblastic lymphoma; cranial radiotherapy was removed for more than 90 percent of patients without excess relapse. | |
AHOD1331 NCT02166463 | 3 | Positive | Newly diagnosed high-risk classical Hodgkin lymphoma (stage IIB with bulk, IIIB, IVA or IVB) in patients aged 2 to 21: five cycles of brentuximab vedotin with doxorubicin, vincristine, etoposide, prednisone and cyclophosphamide against standard ABVE-PC, with PET-guided involved-site radiotherapy for slow-responding lesions | Three-year event-free survival 92.1 percent with brentuximab vedotin plus AVEPC against 82.5 percent with ABVE-PC (hazard ratio 0.41, p < 0.001), with no increase in toxicity; approved for children in the United States in November 2022. | |
DETERMINATION NCT01208662 | 3 | Positive | Newly diagnosed multiple myeloma in patients eligible for transplant: lenalidomide, bortezomib and dexamethasone with early autologous stem-cell transplant against the same regimen without transplant, both followed by lenalidomide maintenance until progression | Early autologous transplant added to RVd and lenalidomide maintenance prolonged progression-free survival; overall survival did not differ at the primary analysis. | |
| 3 | Active | A Phase 3 Randomized, Placebo-controlled Double-blind Study of JNJ-56021927 in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC) | - | ||
| 3 | Completed | A Randomized, Open-Label, Multicenter, Phase 3 Study of Rovalpituzumab Tesirine Compared With Topotecan for Subjects With Advanced or Metastatic DLL3high Small Cell Lung Cancer (SCLC) Who Have First Disease Progression During or Following Front-Line Platinum-Based Chemotherapy (TAHOE) | - | ||
| 3 | - | A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Subjects With Extensive Stage Small Cell Lung Cancer (MERU) | - | ||
| 3 | Completed | Randomized, Multicenter, Open-label, Phase III Study of Plitidepsin in Combination With Dexamethasone vs. Dexamethasone Alone in Patients With Relapsed/Refractory Multiple Myeloma | - | ||
AHL2011 NCT01358747 | 3 | Positive | Aged 16 to 60 with newly diagnosed advanced Hodgkin lymphoma: six cycles of escalated BEACOPP against a switch to ABVD after a negative scan at two cycles | Five-year progression-free survival 85.7 against 86.2 per cent when a negative interim scan allowed a switch to ABVD, with grade 3 to 4 anaemia falling from 69 to 28 per cent. | |
Alliance/CALGB 50303 NCT00118209 | 3 | Negative | Untreated diffuse large B-cell lymphoma: six cycles of dose-adjusted EPOCH-R against six cycles of R-CHOP | No difference in progression-free survival (hazard ratio 0.93) or overall survival (1.09) against R-CHOP, with substantially more febrile neutropenia, mucositis and neuropathy. | |
CARD NCT02485691 | 3 | Positive | Metastatic castration-resistant prostate cancer previously treated with docetaxel and with progression within 12 months on abiraterone or enzalutamide: cabazitaxel 25 mg/m2 every 3 weeks with prednisone and granulocyte colony-stimulating factor, against the other androgen receptor pathway inhibitor, with imaging-based progression-free survival as the primary endpoint | Median imaging-based progression-free survival 8.0 against 3.7 months (hazard ratio 0.54, 95 percent confidence interval 0.40 to 0.73) and overall survival 13.6 against 11.0 months (0.64, 0.46 to 0.89) for cabazitaxel against a second androgen receptor pathway inhibitor. | |
CASSIOPEIA NCT02541383 | 3 | Positive | Transplant-eligible newly diagnosed multiple myeloma: bortezomib, thalidomide and dexamethasone (VTd) induction and consolidation with or without daratumumab, then daratumumab maintenance or observation | Daratumumab added to VTd increased stringent complete responses and lengthened progression-free survival; approved for transplant-eligible myeloma in 2019 (EU) and 2020 (US). | |
ERA 223 NCT02043678 | 3 | Negative | Chemotherapy-naive, asymptomatic or mildly symptomatic castration-resistant prostate cancer with bone metastases: abiraterone acetate 1000 mg daily with prednisone or prednisolone 5 mg twice daily for everyone, plus up to six intravenous injections of radium-223 at 55 kBq/kg or placebo every 4 weeks, with symptomatic skeletal event-free survival as the primary endpoint | Median symptomatic skeletal event-free survival 22.3 against 26.0 months (hazard ratio 1.122, 95 percent confidence interval 0.917 to 1.374, p=0.2636): no benefit. Fractures of any grade in 29 against 11 percent, grade 3 to 4 fractures in 9 against 3 percent. | |
FLYER NCT00278421 | 3 | Positive | Aged 18 to 60 with stage I or II aggressive B-cell lymphoma, normal lactate dehydrogenase, no bulk: four cycles of R-CHOP with six doses of rituximab against six cycles of R-CHOP | Three-year progression-free survival 96 per cent with four cycles of R-CHOP plus two extra rituximab doses, non-inferior to six cycles, with roughly a quarter fewer adverse events. | |
MAIA NCT02252172 | 3 | Positive | Newly diagnosed multiple myeloma in patients not eligible for autologous transplant: daratumumab with lenalidomide and dexamethasone against lenalidomide and dexamethasone, both continued until progression | Daratumumab, lenalidomide and dexamethasone improved progression-free and later overall survival over lenalidomide and dexamethasone in transplant-ineligible newly diagnosed myeloma; approved in June 2019. | |
PRIMA NCT00140582 | 3 | Mixed | High tumour burden follicular lymphoma responding to first-line immunochemotherapy: two years of rituximab maintenance against observation | Median progression-free survival 10.5 against 4.1 years (hazard ratio 0.61) with no difference in ten-year overall survival, which was about 80 per cent in both arms. | |
| 3 | Completed | A Phase III Study of Risk Directed Therapy for Infants With Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; NSC#617807) | - | ||
ECHELON-2 NCT01777152 | 3 | Positive | Untreated CD30-positive peripheral T-cell lymphoma: brentuximab vedotin with cyclophosphamide, doxorubicin and prednisone (A+CHP) against CHOP | A+CHP improved progression-free and overall survival over CHOP in CD30-positive peripheral T-cell lymphoma; approved in November 2018. | |
RELEVANCE NCT01476787 | 3 | Mixed | Previously untreated advanced follicular lymphoma needing treatment: rituximab plus lenalidomide (R2) against rituximab plus the investigator's chemotherapy (R-CHOP, R-CVP or R-bendamustine), both followed by rituximab maintenance, with complete response at 120 weeks and progression-free survival as co-primary endpoints | Complete response at 120 weeks 48 percent with rituximab-lenalidomide against 53 percent with rituximab-chemotherapy (p 0.13) and median progression-free survival 120.2 against 123.8 months (hazard ratio 0.92): not superior, with similar efficacy and a different safety profile. | |
TROG 99.03 NCT00115700 | 3 | Positive | Stage I or II low-grade follicular lymphoma: involved-field radiotherapy alone against radiotherapy followed by six cycles of CVP, with rituximab added from 2006 | Ten-year progression-free survival 59 against 41 per cent when systemic therapy followed radiotherapy (hazard ratio 0.57, p = 0.033), with no significant overall survival difference. |
No recorded escape route names this target.
No pathway diagram carries this target as a node.
No companion diagnostic in the registry measures this target.
No model entry for this target yet; check the cancer entries on the models page.
No open questions recorded for this target yet. Suggest one.
Query for this target: (TITLE:"Glucocorticoid receptor" OR ABSTRACT:"Glucocorticoid receptor" OR TITLE:"NR3C1" OR ABSTRACT:"NR3C1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Glucocorticoid receptor (NR3C1), not a curated reading list.
The dossier as machine-readable JSON, at /api/v1/dossiers/glucocorticoid-receptor.json: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/glucocorticoid-receptor.json. Licence CC BY-NC 4.0.